Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $9,063 - $10,339
-32 Reduced 0.06%
57,963 $18.3 Million
Q4 2022

Jan 23, 2023

SELL
$285.76 - $321.48 $16.2 Million - $18.2 Million
-56,701 Reduced 49.44%
57,995 $0
Q3 2022

Oct 18, 2022

SELL
$273.83 - $305.53 $42.6 Million - $47.5 Million
-155,620 Reduced 57.57%
114,696 $33.2 Million
Q2 2022

Jul 15, 2022

SELL
$234.96 - $292.55 $50,986 - $63,483
-217 Reduced 0.08%
270,316 $76.2 Million
Q1 2022

Apr 14, 2022

BUY
$221.42 - $260.97 $2.61 Million - $3.07 Million
11,775 Added 4.55%
270,533 $70.6 Million
Q4 2021

Jan 14, 2022

BUY
$177.01 - $223.45 $2.19 Million - $2.77 Million
12,385 Added 5.03%
258,758 $56.8 Million
Q3 2021

Oct 13, 2021

BUY
$181.39 - $202.99 $15 Million - $16.8 Million
82,519 Added 50.36%
246,373 $44.7 Million
Q2 2021

Jul 23, 2021

BUY
$187.49 - $221.1 $30.7 Million - $36.2 Million
163,854 New
163,854 $33 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Scout Investments, Inc. Portfolio

Follow Scout Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scout Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scout Investments, Inc. with notifications on news.